Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of Epicardial Adipose Tissue on Infarct Size and Left Ventricular Systolic Function in Patients with Anterior ST-Segment Elevation Myocardial Infarction

  • Gavara Doñate, Jose|||0000-0002-3483-7066
  • Merenciano, Héctor|||0000-0002-1734-0381
  • Llopis-Lorente, Jordi|||0000-0002-3958-8062
  • Molina-Garcia, Tamara
  • Perez-Solé, Nerea|||0000-0003-3527-0337
  • de Dios, Elena
  • Marcos-Garces, Víctor
  • Monmeneu, José V.
  • Lopez-Lereu, María P.
  • Canoves, Joaquim
  • Bonanad, Clara
  • Moratal, David|||0000-0002-2825-3646
  • Núñez, Julio|||0000-0003-1672-7119
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Sanchis, Juan|||0000-0003-0797-8709
  • Chorro, Francisco J.
  • Rios-Navarro, Cesar|||0000-0002-6405-6279
  • Bodi, Vicente|||0000-0001-6425-5828
We aimed to assess the correlation of cardiovascular magnetic resonance (CMR)-derived epicardial adipose tissue (EAT) with infarct size (IS) and residual systolic function in ST-segment elevation myocardial infarction (STEMI). We enrolled patients discharged for a first anterior reperfused STEMI submitted to undergo CMR. EAT, left ventricular (LV) ejection fraction (LVEF), and IS were quantified at the 1-week (n = 221) and at 6-month CMR (n = 167). At 1-week CMR, mean EAT was 31 ± 13 mL/m. Patients with high EAT volume (n = 72) showed larger 1-week IS. After adjustment, EAT extent was independently related to 1-week IS. In patients with large IS at 1 week (>30% of LV mass, n = 88), those with high EAT showed more preserved 6-month LVEF. This association persisted after adjustment and in a 1:1 propensity score-matched patient subset. Overall, EAT decreased at 6 months. In patients with large IS, a greater reduction of EAT was associated with more preserved 6-month LVEF. In STEMI, a higher presence of EAT was associated with a larger IS. Nevertheless, in patients with large infarctions, high EAT and greater subsequent EAT reduction were linked to more preserved LVEF in the chronic phase. This dual and paradoxical effect of EAT fuels the need for further research in this field.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure

  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Barallat, Jaume|||0000-0003-3493-5958
  • Bodi, Vicente|||0000-0001-6425-5828
  • Miñana, Gema|||0000-0001-8777-2588
  • Pastor, M. Cruz
  • Sanchis, Juan|||0000-0003-0797-8709
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Our aim was to evaluate the association between the soluble form of neprilysin () levels and long-term all-cause, cardiovascular, and acute heart failure () recurrent admissions in an ambulatory cohort of patients with heart failure. has emerged as a new biomarker with promising implications for prognosis and therapy in patients with heart failure. Reducing the recurrent admission rate of heart failure patients has become an important target of public health planning strategies. We measured levels in 1021 consecutive ambulatory heart failure patients. End points were the number of all-cause, cardiovascular, and hospitalizations during follow-up. We used covariate-adjusted incidence rate ratios to identify associations. At a median follow-up of 3.4 years (interquartile range: 1.8-5.7), 391 (38.3%) patients died, 477 (46.7%) patients had 1901 all-cause admissions, 324 (31.7%) patients had 770 cardiovascular admissions, and 218 (21.4%) patients had 488 admissions. The medians for and amino-terminal pro-brain natriuretic peptide were 0.64 ng/mL (interquartile range: 0.39-1.22) and 1248 pg/mL (interquartile range: 538-2825), respectively. In a multivariate setting, the adjusted incidence rate ratios for the top (>1.22 ng/mL) versus the bottom (≤0.39 ng/mL) quartiles of were 1.37 (95% confidence interval: 1.03-1.82), P =0.032; 1.51 (95% confidence interval: 1.10-2.06), P =0.010; and 1.51 (95% confidence interval: 1.05-2.16), P =0.026 for all-cause, cardiovascular, and admissions, respectively. Elevated levels predicted an increased risk of recurrent all-cause, cardiovascular, and admissions in ambulatory patients with heart failure.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure

  • Bertomeu-González, Vicente|||0000-0001-5309-0562
  • Facila Rubio, Lorenzo|||0000-0003-1402-4364
  • Palau, Patricia|||0000-0001-5040-0924
  • Miñana, Gema|||0000-0001-8777-2588
  • Núñez, Gonzalo
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Santas, Enrique
  • Núñez, Eduardo
  • Bodi, Vicente|||0000-0001-6425-5828
  • Chorro, Francisco J.
  • Cordero, Alberto|||0000-0003-0000-7109
  • Sanchis, Juan|||0000-0003-0797-8709
  • Lupón, Josep|||0000-0002-5601-9611
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
Type 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and is related with worse outcomes. Insulin treatment is associated with sodium and water retention, weight gain, and hypoglycaemia-all pathophysiological mechanisms related to HF decompensation. This study aimed to evaluate the association between insulin treatment and the risk of 1 year readmission for HF in patients discharged for acute HF. We prospectively included 2895 consecutive patients discharged after an episode of acute HF in a single tertiary hospital. Multivariable Cox regression, adapted for competing events, was used to assess the association between insulin treatment and 1 year readmission for HF in patients discharged after acute HF. Participants' mean age was 73.4 ± 11.2 years, 50.8% were women, 44.7% had T2DM [including 527 (18.2%) on insulin therapy], and 52.7% had preserved ejection fraction. At 1 year follow-up, 518 (17.9%) patients had died and 693 (23.9%) were readmitted for HF. The crude risk of readmission for HF was higher in patients on insulin, with no differences in 1 year mortality. After multivariable adjustment, patients on insulin were at significantly higher risk of 1 year readmission for HF than patients with diabetes who were not on insulin (hazard ratio 1.28; 95% confidence interval 1.04-1.59, P = 0.022) and patients without diabetes (hazard ratio 1.26; 95% confidence interval 1.02-1.55, P = 0.035). Following acute HF, patients with T2DM on insulin therapy are at increased risk of readmission for HF. Further studies unravelling the mechanisms behind this association are warranted.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients

  • Pacho Pacho, Cristina
  • Domingo, Mar|||0000-0002-2935-1272
  • Núñez Aragón, Raquel
  • Lupón, Josep|||0000-0002-5601-9611
  • Núñez, Julio|||0000-0003-1672-7119
  • Barallat, Jaume|||0000-0003-3493-5958
  • Moliner, P.|||0000-0002-5511-8597
  • de Antonio Ferrer, Marta|||0000-0002-4319-797X
  • Santesmases Ejarque, Javier|||0000-0002-1226-1617
  • Cediel, Germán|||0000-0001-9667-7507
  • Roura, Santiago|||0000-0003-4063-9661
  • Pastor, M. Cruz
  • Tor Aguilera, Jordi|||0000-0002-5355-9110
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
Heart failure (HF) is associated with a high rate of readmissions within 30 days post-discharge and in the following year, especially in frail elderly patients. Biomarker data are scarce in this high-risk population. This study assessed the value of early post-discharge circulating levels of ST2, NT-proBNP, CA125, and hs-TnI for predicting 30-day and 1-year outcomes in comorbid frail elderly patients with HF with mainly preserved ejection fraction (HFpEF). Blood samples were obtained at the first visit shortly after discharge (4.9 ± 2 days). The primary endpoint was the composite of all-cause mortality or HF-related rehospitalization at 30 days and at 1 year. All-cause mortality alone at one year was also a major endpoint. HF-related rehospitalizations alone were secondary end-points. From February 2014 to November 2016, 522 consecutive patients attending the STOP-HF Clinic were included (57.1% women, age 82 ± 8.7 years, mean Barthel index 70 ± 25, mean Charlson comorbidity index 5.6 ± 2.2). The composite endpoint occurred in 8.6% patients at 30 days and in 38.5% at 1 year. In multivariable analysis, ST2 [hazard ratio (HR) 1.53; 95% CI 1.19-1.97; p = 0.001] was the only predictive biomarker at 30 days; at 1 year, both ST2 (HR 1.34; 95% CI 1.15-1.56; p < 0.001) and NT-proBNP (HR 1.19; 95% CI 1.02-1.40; p = 0.03) remained significant. The addition of ST2 and NT-proBNP into a clinical predictive model increased the AUC from 0.70 to 0.75 at 30 days (p = 0.02) and from 0.71 to 0.74 at 1 year (p < 0.05). For all-cause death at 1 year, ST2 (HR 1.50; 95% CI 1.26-1.80; p < 0.001), and CA125 (HR 1.41; 95% CI 1.21-1.63; p < 0.001) remained independent predictors in multivariable analysis. The addition of ST2 and CA125 into a clinical predictive model increased the AUC from 0.74 to 0.78 (p = 0.03). For HF-related hospitalizations, ST2 was the only predictive biomarker in multivariable analyses, both at 30 days and at 1 year. In a comorbid frail elderly population with HFpEF, ST2 outperformed NT-proBNP for predicting the risk of all-cause mortality or HF-related rehospitalization. ST2, a surrogate marker of inflammation and fibrosis, may be a better predictive marker in high-risk HFpEF.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations

  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Revuelta-López, Elena|||0000-0001-8962-5936
  • Miñana, Gema|||0000-0001-8777-2588
  • Barallat, Jaume|||0000-0003-3493-5958
  • Bodi, Vicente|||0000-0001-6425-5828
  • Sanchis, Juan|||0000-0003-0797-8709
  • Aimo, Alberto|||0000-0001-9129-9519
  • Emdin, Michele
  • Lupón, Josep|||0000-0002-5601-9611
  • Husser, Oliver
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
A higher neprilysin activity has been suggested in women. In this retrospective analysis, we evaluated the association of sex and body mass index (BMI) with soluble neprilysin (sNEP) and recurrent admissions among 1021 consecutive HF outpatients. The primary and secondary endpoints were the number of HF hospitalizations and all-cause mortality, respectively. The association between sNEP with either endpoint was evaluated across sex and BMI categories (≥ 25 kg/m 2 vs. < 25 kg/m 2). Bivariate count regression (Poisson) was used, and risk estimates were expressed as incidence rates ratio (IRR). During a median follow-up of 6.65 years (percentile 25%-percentile 75%:2.83-10.25), 702 (68.76%) patients died, and 406 (40%) had at least 1 HF hospitalization. Median values of sNEP and BMI were 0.64 ng/mL (0.39-1.22), and 26.9 kg/m 2 (24.3-30.4), respectively. Left ventricle ejection fraction was < 40% in 78.9% of patients, and 28% were women. In multivariable analysis, sNEP (main effect) was positively associated with HF hospitalizations (p = 0.001) but not with mortality (p = 0.241). The predictive value of sNEP for HF hospitalizations varied non-linearly across sex and BMI categories (p -value for interaction = 0.003), with significant and positive effect only on women with BMI ≥ 25 kg/m 2 (p = 0.039). For instance, compared to men, women with sNEP of 1.22 ng/mL (percentile 75%) showed a significantly increased risk (IRRs: 1.26; 95% CI: 1.05-1.53). The interaction analysis for mortality did not support a differential prognostic effect for sNEP (p = 0.072). In conclusion, higher sNEP levels in overweight women better predicted an increased risk of HF hospitalization.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

HDL Function and Size in Patients with On-Target LDL Plasma Levels and a First-Onset ACS

  • Cordero, Alberto|||0000-0003-0000-7109
  • Muñoz-García, Natàlia|||0000-0002-2982-8982
  • Padró, Teresa|||0000-0003-1921-954X
  • Vilahur, Gemma|||0000-0002-2828-8873
  • Bertomeu-González, Vicente|||0000-0001-5309-0562
  • Escribano, David
  • Flores, Emilio|||0000-0001-7524-0808
  • Zuazola, Pilar
  • Badimon, Lina|||0000-0002-9162-2459
Patients admitted for acute coronary syndrome (ACS) usually have high cardiovascular risk scores with low levels of high-density lipoprotein cholesterol (HDL-C) and high low-density lipoprotein cholesterol (LDL-C) levels. Here, we investigated the role of lipoprotein functionality as well as particle number and size in patients with a first-onset ACS with on-target LDL-C levels. Ninety-seven patients with chest pain and first-onset ACS with LDL-C levels of 100 ± 4 mg/dL and non-HDL-C levels of 128 ± 4.0 mg/dL were included in the study. Patients were categorized as ACS and non-ACS after all diagnostic tests were performed (electrocardiogram, echocardiogram, troponin levels and angiography) on admission. HDL-C and LDL-C functionality and particle number/size by nuclear magnetic resonance (NMR) were blindly investigated. A group of matched healthy volunteers (n = 31) was included as a reference for these novel laboratory variables. LDL susceptibility to oxidation was higher and HDL-antioxidant capacity lower in the ACS patients than in the non-ACS individuals. ACS patients had lower HDL-C and Apolipoprotein A-I levels than non-ACS patients despite the same prevalence of classical cardiovascular risk factors. Cholesterol efflux potential was impaired only in the ACS patients. ACS-STEMI (Acute Coronary Syndrome-ST-segment-elevation myocardial infarction) patients, had a larger HDL particle diameter than non-ACS individuals (8.4 ± 0.02 vs. 8.3 ± 0.02 and, ANOVA test, p = 0.004). In conclusion, patients admitted for chest pain with a first-onset ACS and on-target lipid levels had impaired lipoprotein functionality and NMR measured larger HDL particles. This study shows the relevance of HDL functionality rather than HDL-C concentration in ACS patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Venous Leg Compression for Tissue Decongestion in Patients With Worsening Congestive Heart Failure

  • Civera, Jose
  • Miñana, Gema|||0000-0001-8777-2588
  • De la Espriella, Rafael|||0000-0002-8720-3999
  • Santas, Enrique
  • Sastre, Clara
  • Mollar, Anna
  • Conesa, Adriana
  • Martínez, Ana
  • Núñez, Eduardo
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Núñez, Julio|||0000-0003-1672-7119
Venous leg compression (VLC) with elastic bandages has been proposed as a potentially useful strategy for decreasing tissue congestion. We aimed to evaluate the effect of VLC on short-term changes on intravascular refill, assessed by inferior vena cava (IVC) diameter in patients with worsening heart failure (WHF) requiring parenteral furosemide. Additionally, we sought to evaluate whether early changes in IVC were related to short-term decongestion. This is a prospective study in which we included 20 consecutive ambulatory patients with WHF treated with subcutaneous furosemide and VLC for at least 72 h. The endpoints were (a) short-term changes in IVC, (b) the association between decongestion and 3-h IVC changes following VLC. Changes in continuous endpoints and their longitudinal trajectories were estimated with linear mixed regression models. All analyses were adjusted for multiple comparisons. Following administration of subcutaneous furosemide and VLC, we found a significant increase in 3-h IVC diameter (ΔIVC = 1.6 mm, CI 95%: 0.7-2.5; p < 0.001), with a greater increase in those with baseline IVC≤21 mm (2.4 vs. 0.8 mm; p < 0.001). 3-h intravascular refill (increase in IVC≥2 mm) was associated with greater decongestion (natriuresis, weight, peripheral edemas, and dyspnea) in those with baseline IVC≤21 mm but not when IVC>21 mm (p < 0.05 for all comparisons). In this cohort of patients with congestive WHF treated with subcutaneous furosemide and VLC, we found a greater increase in short-term IVC in those with IVC ≤21 mm at baseline. In this subset of patients, a 3-h increase in IVC≥2 mm was associated with greater short-term decongestion.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prognosis Impact of Diabetes in Elderly Women and Men with Non-ST Elevation Acute Coronary Syndrome

  • Díez-Villanueva, Pablo
  • García-Acuña, Jose María
  • Raposeiras-Roubin, Sergio|||0000-0002-6462-4715
  • Barrabés, José A|||0000-0001-7062-6277
  • Cordero, Alberto|||0000-0003-0000-7109
  • Martínez-Sellés, Manuel|||0000-0003-0289-6229
  • Bardají, Alfredo|||0000-0003-1900-6974
  • Marín, Francisco|||0000-0001-7246-7708
  • Ruiz Nodar, Juan Miguel|||0000-0002-8480-0835
  • Vicente-Ibarra, Nuria
  • Alonso Salinas, Gonzalo L.|||0000-0001-5914-8526
  • Cid-Álvarez, Belén
  • Abu-Assi, Emad|||0000-0003-1568-3118
  • Formiga, Frances
  • Núñez, Julio|||0000-0003-1672-7119
  • Núñez, Eduardo
  • Ariza-Solé, Albert|||0000-0002-0819-6656
  • Sanchis, Juan|||0000-0003-0797-8709
Few studies have addressed to date the interaction between sex and diabetes mellitus (DM) in the prognosis of elderly patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). Our aim was to address the role of DM in the prognosis of non-selected elderly patients with NSTEACS according to sex. A retrospective analysis from 11 Spanish NSTEACS registries was conducted, including patients aged ≥70 years. The primary end point was one-year all-cause mortality. A total of 7211 patients were included, 2,770 (38.4%) were women, and 39.9% had DM. Compared with the men, the women were older (79.95 ± 5.75 vs. 78.45 ± 5.43 years, p < 0.001) and more often had a history of hypertension (77% vs. 83.1%, p < 0.01). Anemia and chronic kidney disease were both more common in women. On the other hand, they less frequently had a prior history of arteriosclerotic cardiovascular disease or comorbidities such as peripheral artery disease and chronic pulmonary disease. Women showed a worse clinical profile on admission, though an invasive approach and in-hospital revascularization were both more often performed in men (p < 0.001). At a one-year follow-up, 1090 patients (15%) had died, without a difference between sexes. Male sex was an independent predictor of mortality (HR = 1.15, 95% CI 1.01 to 1.32, p = 0.035), and there was a significant interaction between sex and DM (p = 0.002). DM was strongly associated with mortality in women (HR: 1.45, 95% CI = 1.18-1.78; p < 0.001), but not in men (HR: 0.98, 95% CI = 0.84-1.14; p = 0.787). In conclusion, DM is associated with mortality in older women with NSTEACS, but not in men.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Respiratory syncytial virus vaccination as cardiopulmonary and cardiovascular risk mitigation in adults with heart disease

  • Bonanad, Clara
  • Barrios, Vivencio
  • Barreres, Guillermo
  • García-Collado, Nora
  • Maidana, Daniela
  • Vivas, David
  • Raposeiras, Sergio
  • Fortuny, Elena
  • Segura-Rodríguez, Diego
  • Alonso Salinas, Gonzalo Luis
  • Redondo Marguello, Esther
  • Garcia-Lledó, Alberto
  • García-Blas, Sergio
Background/Objectives: Respiratory syncytial virus (RSV) causes morbidity in older adults with cardiovascular disease, in whom infection may precipitate severe lower respiratory tract disease, hospitalization, functional decline, and cardiovascular destabilization. We evaluate the evidence for RSV vaccination in cardiovascular disease and propose a jurisdiction-adaptable framework for integrating vaccination into cardiovascular care. Methods: Observational studies, randomized trials, pragmatic and test-negative studies, prespecified cardiovascular analyses of DAN-RSV, and eligibility recommendations were narratively synthesized and translated into a pathway encompassing patient identification, eligibility and risk assessment, vaccine delivery and co-administration, documentation, and follow-up. Results: Acute cardiac events are frequent during RSV hospitalization, and cardiovascular risk may persist after infection. Randomized trials establish protection against RSV-associated lower respiratory tract disease and respiratory illness, while real-world studies support effectiveness against RSV-related hospitalization. DAN-RSV reduced all-cause cardiorespiratory hospitalization but did not demonstrate significant reductions in cardiovascular hospitalization, myocardial infarction, heart failure (HF) hospitalization, atrial fibrillation, stroke, cardiovascular death, or major adverse cardiovascular events; observational associations with lower post-vaccination cardiovascular-event rates remain hypothesis-generating. The framework prioritizes adults aged ≥75 years and those aged 50–74 years with high-risk cardiovascular conditions where consistent with national recommendations, embeds vaccination assessment across cardiology, HF, primary care, pharmacy, and long-term care, and incorporates co-administration, documentation, and outcome surveillance. Conclusions: The principal contribution is a pathway for moving RSV vaccination from recommendation to routine preventive care for adults with cardiovascular disease. It anchors implementation in established RSV and cardiorespiratory benefits while treating cardiovascular-event reduction as a research priority rather than a demonstrated indication., This work was funded by Instituto de Salud Carlos III and co-funded by FEDER (Exp. JR21/00041, PI23/01468, CB16/11/00420 and CB16/11/00486).